Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16080067 | 0.93 | GCGR (0.64) | GCGRKMT2ANPC1RAB9AKDM4E | |
| SCHEMBL16079418 | 0.93 | MAPT (0.55) | GCGRKMT2ANPC1RAB9AKDM4E | |
| SCHEMBL14907017 | 0.88 | LMNA (0.56) | GCGRKMT2ANPC1RAB9AKDM4E | |
| SCHEMBL16080076 | 0.87 | LMNA (0.57) | GCGRKMT2ANPC1RAB9AKDM4E | |
| SCHEMBL14906909 | 0.85 | LMNA (0.60) | GCGRKMT2ANPC1RAB9AKDM4E | |
| SCHEMBL14907012 | 0.85 | LMNA (0.52) | KMT2ANPC1RAB9AKDM4EMAPT | |
| SCHEMBL14906949 | 0.83 | MAPT (0.51) | KMT2ANPC1RAB9AKDM4EMAPT | |
| SCHEMBL12387736 | 0.80 | GCGR (0.62) | GCGRKMT2ANPC1RAB9AKDM4E | |
| SCHEMBL21211569 | 0.80 | MAPT (0.71) | GCGRKMT2ANPC1RAB9AKDM4E | |
| SCHEMBL14906947 | 0.80 | GCGR (0.54) | GCGRKMT2ANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873661-B2 | Small molecule malarial Aldolase-TRAP enhancers and glideosome inhibitors | NEW YORK UNIVERSITY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20140275088-A1 | SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2014-09-18 | — | — | US | disclosed |
| WO-2013063243-A1 | SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS | NEW YORK UNIVERSITY (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275088-A1 | SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS | ALDOA, DERA, TALDO1 | GCGR 2311/4885KMT2A 929/4885NPC1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.